b'The path forwardWhensponsorsarriveattheirEOP2Ameetingwiththeanswers tothecriticalCNS-specificquestionslargelyaddressed,thepath forward for their drug has less unknowns. Having already studied the salient issues, you can be more confident in the trials you will need to conduct in future phases, and you will have the opportunity to fully understand the future budget and timeline implications. Determining if your drug is at less risk for critical safety factors such as abuse potentialorimpairingeffectscanprovideimportantinformation toleverageregulatoryreviewstatusand/orfundingorinvestment opportunities. Understanding your program early in development and creating a robust strategy for your regulatory meetings will enable better accuracy in predicting timelines and budgetary needs for your programs.PartneringwithaCROthathasrelevant,current,andextensive experience in the analysis of these additional considerations for a CNS agent is crucial. Altasciences is that CRO.See our relevant expertise here:Human Abuse PotentialCNS/Cognitive/Driving SimulationThe Altascientist - Scientific Journal:Studying the Effects of Drugs on DrivingThe Altascientist - Scientific Journal:Assessing Human Abuse Potential to Limit the Misuse and Abuse of Prescription Drugs'